Insulin-like growth factor 2: A poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma

Anne R. Van Arsdale, Rebecca C. Arend, Maria J. Cossio, Britt K. Erickson, Yanhua Wang, David W. Doo, Charles A. Leath, Gary L. Goldberg, Gloria S. Huang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The objective of this study was to investigate the relationship of insulin-like growth factor 2 (IGF2) expression and survival in women with uterine carcinosarcoma (UCS). Insulin-like growth factor 2 protein expression was determined by immunohistochemical staining of tumor tissues from 103 patients with UCS. The H-score (product of staining intensity and percentage positive cells) was quantified for the epithelial cytoplasmic (EC), epithelial nuclear (EN), and malignant stromal compartments. Multivariable Cox proportional hazard regression models were used to examine the relationship of IGF2 levels with progression-free survival (PFS) and overall survival (OS). Adjusting for stage, race, and adjuvant therapy, PFS and OS were reduced in patients with high IGF2 (H-score ≥ median) in the EC and EN compartments. Black race was independently associated with reduced PFS and OS in patients with early-stage disease, and IGF2 levels in the EC were higher in black than in white patients (P = 0.02, Wilcoxon test). In a race-stratified multivariable analysis, high IGF2 in the epithelial compartments more than doubled the risk of death in black women; HR = 2.43 (95% CI: 1.18-5.01, P = 0.02) for high IGF2 in the EC; and HR = 2.34 (95% CI: 1.25-4.39, P = 0.008) for high IGF2 in the EN. In conclusion, high tumor IGF2 expression is an independent risk factor for reduced PFS and OS in UCS. Black women have elevated tumor IGF2 compared with white women, and decreased survival associated with high IGF2. These findings identify IGF2 as a candidate biomarker for survival linked to racial disparity in women with UCS.

Original languageEnglish (US)
JournalCancer Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Carcinosarcoma
Somatomedins
Biomarkers
Survival
Disease-Free Survival
Staining and Labeling
Neoplasms
Plague
Proportional Hazards Models

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Insulin-like growth factor 2 : A poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. / Van Arsdale, Anne R.; Arend, Rebecca C.; Cossio, Maria J.; Erickson, Britt K.; Wang, Yanhua; Doo, David W.; Leath, Charles A.; Goldberg, Gary L.; Huang, Gloria S.

In: Cancer Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Van Arsdale, Anne R. ; Arend, Rebecca C. ; Cossio, Maria J. ; Erickson, Britt K. ; Wang, Yanhua ; Doo, David W. ; Leath, Charles A. ; Goldberg, Gary L. ; Huang, Gloria S. / Insulin-like growth factor 2 : A poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. In: Cancer Medicine. 2018.
@article{22650aae69d741ec9c5c4b895fb7247b,
title = "Insulin-like growth factor 2: A poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma",
abstract = "The objective of this study was to investigate the relationship of insulin-like growth factor 2 (IGF2) expression and survival in women with uterine carcinosarcoma (UCS). Insulin-like growth factor 2 protein expression was determined by immunohistochemical staining of tumor tissues from 103 patients with UCS. The H-score (product of staining intensity and percentage positive cells) was quantified for the epithelial cytoplasmic (EC), epithelial nuclear (EN), and malignant stromal compartments. Multivariable Cox proportional hazard regression models were used to examine the relationship of IGF2 levels with progression-free survival (PFS) and overall survival (OS). Adjusting for stage, race, and adjuvant therapy, PFS and OS were reduced in patients with high IGF2 (H-score ≥ median) in the EC and EN compartments. Black race was independently associated with reduced PFS and OS in patients with early-stage disease, and IGF2 levels in the EC were higher in black than in white patients (P = 0.02, Wilcoxon test). In a race-stratified multivariable analysis, high IGF2 in the epithelial compartments more than doubled the risk of death in black women; HR = 2.43 (95{\%} CI: 1.18-5.01, P = 0.02) for high IGF2 in the EC; and HR = 2.34 (95{\%} CI: 1.25-4.39, P = 0.008) for high IGF2 in the EN. In conclusion, high tumor IGF2 expression is an independent risk factor for reduced PFS and OS in UCS. Black women have elevated tumor IGF2 compared with white women, and decreased survival associated with high IGF2. These findings identify IGF2 as a candidate biomarker for survival linked to racial disparity in women with UCS.",
author = "{Van Arsdale}, {Anne R.} and Arend, {Rebecca C.} and Cossio, {Maria J.} and Erickson, {Britt K.} and Yanhua Wang and Doo, {David W.} and Leath, {Charles A.} and Goldberg, {Gary L.} and Huang, {Gloria S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cam4.1335",
language = "English (US)",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Insulin-like growth factor 2

T2 - A poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma

AU - Van Arsdale, Anne R.

AU - Arend, Rebecca C.

AU - Cossio, Maria J.

AU - Erickson, Britt K.

AU - Wang, Yanhua

AU - Doo, David W.

AU - Leath, Charles A.

AU - Goldberg, Gary L.

AU - Huang, Gloria S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The objective of this study was to investigate the relationship of insulin-like growth factor 2 (IGF2) expression and survival in women with uterine carcinosarcoma (UCS). Insulin-like growth factor 2 protein expression was determined by immunohistochemical staining of tumor tissues from 103 patients with UCS. The H-score (product of staining intensity and percentage positive cells) was quantified for the epithelial cytoplasmic (EC), epithelial nuclear (EN), and malignant stromal compartments. Multivariable Cox proportional hazard regression models were used to examine the relationship of IGF2 levels with progression-free survival (PFS) and overall survival (OS). Adjusting for stage, race, and adjuvant therapy, PFS and OS were reduced in patients with high IGF2 (H-score ≥ median) in the EC and EN compartments. Black race was independently associated with reduced PFS and OS in patients with early-stage disease, and IGF2 levels in the EC were higher in black than in white patients (P = 0.02, Wilcoxon test). In a race-stratified multivariable analysis, high IGF2 in the epithelial compartments more than doubled the risk of death in black women; HR = 2.43 (95% CI: 1.18-5.01, P = 0.02) for high IGF2 in the EC; and HR = 2.34 (95% CI: 1.25-4.39, P = 0.008) for high IGF2 in the EN. In conclusion, high tumor IGF2 expression is an independent risk factor for reduced PFS and OS in UCS. Black women have elevated tumor IGF2 compared with white women, and decreased survival associated with high IGF2. These findings identify IGF2 as a candidate biomarker for survival linked to racial disparity in women with UCS.

AB - The objective of this study was to investigate the relationship of insulin-like growth factor 2 (IGF2) expression and survival in women with uterine carcinosarcoma (UCS). Insulin-like growth factor 2 protein expression was determined by immunohistochemical staining of tumor tissues from 103 patients with UCS. The H-score (product of staining intensity and percentage positive cells) was quantified for the epithelial cytoplasmic (EC), epithelial nuclear (EN), and malignant stromal compartments. Multivariable Cox proportional hazard regression models were used to examine the relationship of IGF2 levels with progression-free survival (PFS) and overall survival (OS). Adjusting for stage, race, and adjuvant therapy, PFS and OS were reduced in patients with high IGF2 (H-score ≥ median) in the EC and EN compartments. Black race was independently associated with reduced PFS and OS in patients with early-stage disease, and IGF2 levels in the EC were higher in black than in white patients (P = 0.02, Wilcoxon test). In a race-stratified multivariable analysis, high IGF2 in the epithelial compartments more than doubled the risk of death in black women; HR = 2.43 (95% CI: 1.18-5.01, P = 0.02) for high IGF2 in the EC; and HR = 2.34 (95% CI: 1.25-4.39, P = 0.008) for high IGF2 in the EN. In conclusion, high tumor IGF2 expression is an independent risk factor for reduced PFS and OS in UCS. Black women have elevated tumor IGF2 compared with white women, and decreased survival associated with high IGF2. These findings identify IGF2 as a candidate biomarker for survival linked to racial disparity in women with UCS.

UR - http://www.scopus.com/inward/record.url?scp=85042102222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042102222&partnerID=8YFLogxK

U2 - 10.1002/cam4.1335

DO - 10.1002/cam4.1335

M3 - Article

C2 - 29455465

AN - SCOPUS:85042102222

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -